Notably, individuals with PD and coexisting metabolic comorbgidities such as insulin resistance or obesity appear to derive greater clinical and cognitive benefits from GLP-1 RA therapy [62, 63]. This evidence concerns the gene GLP1R and obesity due to melanocortin 4 receptor deficiency.